Trial Profile
Open Label Phase II/III, Multicenter, Trial to Assess the Efficacy, Safety, Tolerance, and Pharmacokinetics of Sofosbuvir Plus Ravidasvir in HCV (+/- HIV) Chronically Infected Adults With no or Compensated Cirrhosis in Thailand and Malaysia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Ravidasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms STORM-C; STORM-C-1
- 18 Jan 2021 Planned End Date changed from 1 Dec 2023 to 1 Mar 2024.
- 18 Jan 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Aug 2021.
- 18 Jan 2021 Status changed from recruiting to active, no longer recruiting.